by Government contain details of sales turnover;

(b) if so, what are the basis of stating that sales turnover is not monitored; and

(c) since all the companies have furnished the details at the time of promulgation of DPCO, 1987 what are the reasons for which the details of sales turnover of major brands like Dilosyn, Benadryl, Evion, Berin, Celin DPT etc. have not been furnished?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) to (c) Form 2 is required to be submitted in the case of scheduled formulations only. Form 4 is required to be submitted in the case of new packs of Non Scheduled formulations introduced during the period of 6 months from Jan. to June or July to Dec. as the case may be or in the case of non-scheduled formulations packs prices of which are revised durig the said period. Form 6 is meant for determining the profitability of the drug companies in formulation activity. Sales turn-over of individual formulations is not monitored in any of the cases.

Prices of tetracycline formulations

3281. SHRI M. KADHARSHA: Will the Minister of INDUSTRY be pleased to state:

(a) hat are the names of the various Tetracyclines which were the subject matter of litigation in the Supreme Court and what was the production of each from the date of litigation to the date of promulgation of DPCO, 1987;

(b) what were the prices of formulations charged by the company and those which were approved by Government along with the production of each formulation, yearwise;

(c) at what rate the recovery was made in respect of each bulk drug and each formulation; and

(d) whether the production of each of the bulk drugs and formulations is monitored?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) and (d) The production of Tetracycline bulk drug monitored by the Department for the years 1982-83 to 1985-86 is given below:

Year	Production (Tonnes) Total	Production by M/s. Cyanamid Ltd.
1982-83	209.14	8.91
1983-84	208.54	2.19
1984-85	227.04	11.10
1985-86	227.39	10.50

(b) The details of prices of formulations charged by the company are quite voluminous. The time and efforts required for collection of these details will not be commensurate with the results likely to be achieved.

(c) The amount recoverable has been calculated with reference to the prices charged by the company and the prices fixed by the Government in respect of formulations.

Recovery of DPEA dues

3282. SHRI JASWANT SINGH:
SHRI JAGESH DESAI:

Will the Minister of INDUSTRY be pleased to refer to the answer to Unstarred Question 641 given in the Rajya Sabha on the 2nd May, 1988 and state:

(a) what are the reasons for keeping the job of recovery under the Drug Prices Eualisation Account on to itself and not getting it done from the BICP or Ministry of Finance;

(b) whether it is a fact that relaxations and concessions have been given to the drug companies so as to minimise the liability; and

(c) whether Government will submit the full details to a committee of Members of Parliament for examination?